|
  
- 现金
- 3543 元
- 精华
- 2
- 帖子
- 2934
- 注册时间
- 2001-10-26
- 最后登录
- 2018-12-25
|
Cuban hepatitis B medication undergoing clinical trials
古巴乙肝的药物正在进行临床试验
Aug 11th, 2015 +
In this article: Cuba, Health, Science, society
The product has been undergoing safety and efficacy tests for several years, stated a CIGB specialist.
古巴药物来治疗慢性乙型肝炎，HeberNasvac，科学家在遗传工程和生物技术中心（CIGB）创建，目前正在进行中的合作，临床试验公司与法国Abivax。
According to Iris Lugo Carro, the clinical trials being carried out by Cuban scientists and Abivax – involving 230 patients from eight Asian countries, and the participation of 50 clinical centers – are being realized under regulation ABX 203.
根据虹膜卢戈卡罗，临床试验正在开展的古巴科学家和Abivax - 包括来自八个亚洲国家的230例患者，以及50个临床中心的参与 - 正在根据第ABX203实现。
To date, the study has been approved by the regulatory authorities of Australia, New Zealand, Singapore, South Korea, Taiwan, Hong Kong, the Philippines and Thailand.
迄今为止，研究已获得澳大利亚，新西兰，新加坡，韩国，台湾，香港，菲律宾和泰国的监管当局。
The trials were designed by high-level sector experts contracted by Abivax, in collaboration with Cuban scientists.
该试验是由Abivax与古巴科学家签约，合作高级别部门的专家设计的。
Satisfactory progress is being made in the investigation being carried out in this region of the world, where Hepatitis Bprevalence ishighest.
The chronic liver disease, caused by the hepatitis B (HBV) virus, is one of the principal causes of liver cancer, cirrhosis of the liver and other illnesses such as ascites, esophageal varices, splenomegaly, all with high mortality rates.
正在取得的调查取得令人满意的进展正在开展在这一地区的世界，在那里肝炎Bprevalence ishighest。
慢性肝病，引起乙型肝炎（乙肝）病毒是肝癌，肝等病症如腹水，食管静脉曲张，脾大肝硬化的主要原因之一，全部采用高死亡率。
HBV causes almost one million deaths every year, according to statistics from the World Health Organization (WHO).
乙肝病毒引起将近一万人死亡，每年，据世界卫生组织（WHO）的统计数据。
HeberNasvac contains the surface and nucleocapsid antigen of the hepatitis B virus, two recombinant proteins manufactured by CIGB.
The therapeutic treatment is either injected or administered nasally, causes fewer adverse reactions and is a more effective antiviral remedy than existing treatments.
HeberNasvac含有乙型肝炎病毒的表面和核衣壳抗原，两种重组蛋白质制造的CIGB。
治疗性治疗要么注射或经鼻给药，引起不良反应少，是一种更有效的抗病毒补救比现有的治疗方法。
A second study is underway in Cuba with the participation of the Ministry of Public Health, in order to optimize the virus treatment plan and find new ways to administer the product.
第二项研究正在进行古巴公共卫生部的参与，以优化病毒治疗方案，并寻找新的方法来管理产品。
Involved in this study are 13 clinics across the entire country, which will benefit 160 Cuban patients. The investigation is currently in the recruitment stage, to find suitable patients suffering from the virus to participate.
参与这项研究是整个国家，这将有利于古巴的160例13诊所。调查目前正处于招聘阶段，寻找合适的病人参与病毒的痛苦。
The CIGB anticipates that HeberNasvac could be made available in Cuba in 2016, after it secures approval from the health register granted by the State Control of Medicines, Equipment and Medical Devices Center.
The HeberNasvac therapeutic medication is supported by patents granted in the most demanding markets.
该CIGB预计HeberNasvac可在2016年提供在古巴，它保证了从授予的药品，设备状态控制和医疗器械中心健康登记批准后。
该HeberNasvac治疗药物是在最苛刻的市场授予专利权的支持。
CIGB scientists, in collaboration with the University of Ehime, Japan; the Bangladesh Liver Foundation and Liver Research Society; the Pasteur Institute in France; the Venezuelan Institute of Scientific Research and the University of Hannover in Germany, have published more than 20 scientific works relating to the product.
CIGB科学家，与爱媛县，日本的大学合作;孟加拉国肝脏基金会和肝脏研究学会;在法国巴斯德研究所;科学研究委内瑞拉研究所和汉诺威在德国的大学，已经发表了超过20与产品的科学著作。
In Cuba, workers responsible for the development of the medication have repeatedly won the Annual Prize awarded by the Academy of Sciences. (PL)
在古巴，负责药品的开发人员曾多次荣获年度大奖颁发院士。（PL） |
|
楼主: zgct
发表于 2015-9-9 21:22
